Parkhurst, M. R. et al. Distinctive neoantigens come up from somatic mutations in sufferers with gastrointestinal cancers. Most cancers Discov. 9, 1022–1035 (2019).
Prickett, T. D. et al. Sturdy full response from metastatic melanoma after switch of autologous T cells recognizing 10 mutated tumor antigens. Most cancers Immunol. Res. 4, 669–678 (2016).
Stevanovic, S. et al. Panorama of immunogenic tumor antigens in profitable immunotherapy of virally induced epithelial most cancers. Science 356, 200–205 (2017).
Tran, E. et al. Most cancers immunotherapy primarily based on mutation-specific CD4+ T cells in a affected person with epithelial most cancers. Science 344, 641–645 (2014).
Zacharakis, N. et al. Breast cancers are immunogenic: immunologic analyses and a section II pilot medical trial utilizing mutation-reactive autologous lymphocytes. J. Clin. Oncol. 40, 1741–1754 (2022).
Crompton, J. G., Sukumar, M. & Restifo, N. P. Uncoupling T-cell enlargement from effector differentiation in cell-based immunotherapy. Immunol. Rev. 257, 264–276 (2014).
Krishna, S. et al. Stem-like CD8 T cells mediate response of adoptive cell immunotherapy in opposition to human most cancers. Science 370, 1328–1334 (2020).
Sade-Feldman, M. et al. Defining T cell states related to response to checkpoint immunotherapy in melanoma. Cell 175, 998–1013.e20 (2018).
Morgan, R. A. et al. Most cancers regression in sufferers after switch of genetically engineered lymphocytes. Science 314, 126–129 (2006).
Robbins, P. F. et al. A pilot trial utilizing lymphocytes genetically engineered with an NY-ESO-1-reactive T-cell receptor: long-term follow-up and correlates with response. Clin. Most cancers Res. 21, 1019–1027 (2015).
Robbins, P. F. et al. Tumor regression in sufferers with metastatic synovial cell sarcoma and melanoma utilizing genetically engineered lymphocytes reactive with NY-ESO-1. J. Clin. Oncol. 29, 917–924 (2011).
Parkhurst, M. R. et al. T cells focusing on carcinoembryonic antigen can mediate regression of metastatic colorectal most cancers however induce extreme transient colitis. Mol. Ther. 19, 620–626 (2011).
Linette, G. P. et al. Cardiovascular toxicity and titin cross-reactivity of affinity-enhanced T cells in myeloma and melanoma. Blood 122, 863–871 (2013).
Morgan, R. A. et al. Most cancers regression and neurological toxicity following anti-MAGE-A3 TCR gene remedy. J. Immunother. 36, 133–151 (2013).
Dudley, M. E., Wunderlich, J. R., Shelton, T. E., Even, J. & Rosenberg, S. A. Era of tumor-infiltrating lymphocyte cultures to be used in adoptive switch remedy for melanoma sufferers. J. Immunother. 26, 332–342 (2003).
Cohen, C. J., Zhao, Y., Zheng, Z., Rosenberg, S. A. & Morgan, R. A. Enhanced antitumor exercise of murine–human hybrid T-cell receptor (TCR) in human lymphocytes is related to improved pairing and TCR/CD3 stability. Most cancers Res. 66, 8878–8886 (2006).
Chatani, P. D. et al. Cell floor marker-based seize of neoantigen-reactive CD8+ T-cell receptors from metastatic tumor digests. J. Immunother. Most cancers 11, e006264 (2023).
Rosenberg, S. A. et al. Sturdy full responses in closely pretreated sufferers with metastatic melanoma utilizing T-cell switch immunotherapy. Clin. Most cancers Res. 17, 4550–4557 (2011).
Wang, Q. J. et al. Identification of T-cell receptors focusing on KRAS-mutated human tumors. Most cancers Immunol. Res. 4, 204–214 (2016).
Foy, S. P. et al. Non-viral precision T cell receptor substitute for customized cell remedy. Nature 615, 687–696 (2023).
Hanada, Ok. I. et al. A phenotypic signature that identifies neoantigen-reactive T cells in recent human lung cancers. Most cancers Cell 40, 479–493 e476 (2022).
Yossef, R. et al. Phenotypic signatures of circulating neoantigen-reactive CD8+ T cells in sufferers with metastatic cancers. Most cancers Cell 41, 2154–2165.e5 (2023).
Cohen, C. J. et al. Isolation of neoantigen-specific T cells from tumor and peripheral lymphocytes. J. Clin. Make investments. 125, 3981–3991 (2015).
Cafri, G. et al. Reminiscence T cells focusing on oncogenic mutations detected in peripheral blood of epithelial most cancers sufferers. Nat. Commun. 10, 449 (2019).
Kim, S. P. et al. Adoptive mobile remedy with autologous tumor-infiltrating lymphocytes and T-cell receptor-engineered T cells focusing on widespread p53 neoantigens in human stable tumors. Most cancers Immunol. Res. 10, 932–946 (2022).
Abate-Daga, D. et al. Expression profiling of TCR-engineered T cells demonstrates overexpression of a number of inhibitory receptors in persisting lymphocytes. Blood 122, 1399–1410 (2013).
Pasetto, A. et al. Tumor- and neoantigen-reactive T-cell receptors may be recognized primarily based on their frequency in recent tumor. Most cancers Immunol. Res. 4, 734–743 (2016).
Favero, F. et al. Sequenza: allele-specific copy quantity and mutation profiles from tumor sequencing knowledge. Ann. Oncol. 26, 64–70 (2015).
McGranahan, N. et al. Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade. Science 351, 1463–1469 (2016).
Roth, A. et al. PyClone: statistical inference of clonal inhabitants construction in most cancers. Nat. Strategies 11, 396–398 (2014).
Dilthey, A. T. et al. HLA*LA–HLA typing from linearly projected graph alignments. Bioinformatics 35, 4394–4396 (2019).
Bai, Y., Wang, D. & Fury, W. PHLAT: inference of high-resolution HLA varieties from RNA and complete exome sequencing. Strategies Mol. Biol. 1802, 193–201 (2018).
McGranahan, N. et al. Allele-specific HLA loss and immune escape in lung most cancers evolution. Cell 171, 1259–1271.e11 (2017).
Rosenberg, S. A. et al. Immunologic and therapeutic analysis of an artificial peptide vaccine for the remedy of sufferers with metastatic melanoma. Nat. Med. 4, 321–327 (1998).
